Navigation Links
AEterna's acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy

AEterna Laboratories Inc., a biopharmaceutical company focused on the development of novel therapeutic treatments in oncology and endocrinology recently acquired the new German based biopharmaceutical company, Zentaris AG. Following this acquisition// the new entity has in the pipeline six clinical stage products and two preclinical stage products, in oncology and one product already approved and marketed for in vitro fertilization in endocrinology. There are also two products in the preclinical stage and one in the clinical stage, in endocrinology.

AEterna's Chairman and CEO, Dr. Eric Dupont, believes that they now have the right partner to develop a leadership position in two growing therapeutic areas, oncology and endocrinology as Zentaris provides experienced management and drug development teams, an already marketed product, a solid financial position with a positive cash flow for 2002, eight additional global pharmaceutical partnerships and an impressive drug discovery platform.

AEterna's and Zentaris' combined clinical development strategy is based on five factors; development costs, competitive environment, involvement of pharmaceutical partners, time to market and potential markets for future drugs. The new structure is expected to drive drug discovery on an ongoing- forward basis through a state-of-the-art drug discovery unit, including a 100,000 proprietary compound library. Gilles Gagnon, President and COO at AEterna added that given the above five factors and and a portfolio of 12 products in development, the strategy for Neovastat will now strictly focus on the two ongoing Phase III studies in kidney cancer and lung cancer. Results of the kidney cancer trial are expected by the first or second quarter of 2003, while those of the lung cancer trial should be disclosed by the end of 2005.

Prof. Dr. Jurgen Engel, Chief Executive Officer at Zentaris concluded that the combined expertise will allow advancement of multiple pro mising preclinical and clinical projects for the development of novel treatments focused on oncology and endocrinology.


'"/>




Related medicine news :

1. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
2. Are cancer patients being taken for a ride?
3. Nervous disorder being treated
4. Benign eye tumors being treated
5. Heart disease in women being under-treated
6. Chance of water births being urged for mums-to-be
7. CPR! How Effectively is it being done ?
8. Men tend to deny being overweight
9. Yoga, ayurveda being documented to stop patent misuse
10. Surgeons being paid triple the amount to cut waiting lists
11. Fund being raised for treatment to HIV positive Libyan kid
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... , ... April 24, 2017 , ... ... laboratory-grade deionized water from the same place. From 101 Water Texas, here are ... Patients and staff can enjoy a continuous supply of pure, fresh, oxygenated water, ...
(Date:4/22/2017)... ... April 22, 2017 , ... PharmacyChecker.com released its first International ... of 70% when buying medication online from Canadian pharmacies verified in the PharmacyChecker ... other countries. The report (chart below) compares U.S. and foreign prices for 20 ...
(Date:4/21/2017)... ... 21, 2017 , ... The staff at Palm Beach Face is proud to announce that their ... London Marathon. Set to take place on April 23rd, the London Marathon has a long ... run as part of team EMPOWER, raising money for the international charity, Smile Train. ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Allegheny County that offers services to communities throughout the greater Pittsburgh metropolitan region, ... charity drive to provide adaptive bicycles for differently-abled children. , Variety the Children’s ...
(Date:4/21/2017)... Kong (PRWEB) , ... April 21, 2017 , ... The ... (U3DP), the first 3D printing facility among higher education institutions in Hong Kong to ... printing, in terms of the range and quantity of facilities in Hong Kong. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
Breaking Medicine Technology: